Adaptive clinical trial

Other Transaction IDV Awarded Last action

Contract number
W911SR2190011
Awardee
Awarding agency
Task orders
0

Award facts

Last date to order
Not on record
IDV ceiling
$38,701,225.84
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
NAICS code
Not on record
Set-aside
No set-aside
Competition
Competed Broad Agency Announcement
Pricing
Other

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

This Other Transaction IDV was awarded by the Joint PEO Chemical and Biological Defense, a U.S. Department of Defense agency, to Dynavax Technologies Corporation. The $38.7 million IDV funds adaptive clinical trials focused on disease prevention and treatment, leveraging Dynavax's expertise in immunology and infectious disease research. As a prime contractor, Dynavax will provide specialized pharmaceutical products and services, including drugs, vaccines, and medical countermeasures, under this IDV structure that allows for the issuance of task orders over an extended period. Dynavax holds several other IDIQ contract vehicles across federal agencies, demonstrating its established capabilities in delivering a range of medical products and research services, particularly in support of national immunization programs and development of countermeasures against chemical and biological threats.

Transactions

Action Obligated Date
Funding Only Action P00016 $22,294
Supplemental Agreement for work within scope P00015 $0
Supplemental Agreement for work within scope P00014 $0
Supplemental Agreement for work within scope P00013 $2,206,413
Funding Only Action P00012 · Adaptive clinical trial to determine if biological response modifier (BRM) can improve the operational utility of the current investigational RF1V vaccine. $1,982,751
Supplemental Agreement for work within scope P00011 · The scope of this agreement is to conduct a GAP analysis of the manufacturing process for the plague vaccine as IT stands from the historical plague vaccine… $3,951,000
Funding Only Action P00010 · RF1V reagent stability testing and plague NHP studies. $1,102,425
Other Administrative Action P00009 $0
Funding Only Action P00008 · RF1V plague vaccine adaptive clinical trial prototype agreement. $344,791
Funding Only Action P00007 · RF1V plague vaccine adaptive clinical trial $828,556
Other Administrative Action P00006 · Incorporate administrative changes to clarify some terms and conditions of the agreement for adaptive clinical trials. No changes to cost/funding. $0
Supplemental Agreement for work within scope P00005 · Add NHP work to continue towards FDA licensure of a vaccine for plague. $2,652,119
Change Order P00004 · Adaptive clinical trial for plague vaccine ongoing r & d efforts. $2,342,503
Supplemental Agreement for work within scope P00003 · Modification to add elisa requalification testing and stability testing for plague adaptive clinical trial r & d efforts. $1,075,597
Other Administrative Action P00002 $0
Supplemental Agreement for work within scope P00001 $463,206
Original award $21,715,491
Show all 17

Quick answers

Who was awarded contract W911SR2190011?

W911SR2190011 was awarded to Dynavax Technologies Corporation by ACC Aberdeen Proving Ground (Army Contracting Command) on September 27, 2021.

How much is contract W911SR2190011 worth?

W911SR2190011's own ceiling is $38,701,226.

Which agency awarded contract W911SR2190011?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2190011, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911SR2190011 competed?

The extent of competition for W911SR2190011 was competed.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login